Multiple sclerosis : clinical and laboratory research
-
Randomized Controlled Trial Multicenter Study
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. ⋯ Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.
-
In multiple sclerosis (MS) regional grey matter (GM) atrophy has been associated with disability progression. ⋯ These results suggested a direct association of disability progression and regional GM atrophy in RRMS.